Results 281 to 290 of about 53,288 (296)
Some of the next articles are maybe not open access.
Itraconazole-induced thrombocytopenia
Cutaneous and Ocular Toxicology, 2016Itraconazole is one of the systemic treatment options for extensive tinea versicolor. A male patient who developed thrombocytopenia during the treatment of tinea versicolor by itraconazole is reported in this manuscript. He was diagnosed to develop thrombocytopenia on the third day of treatment.
openaire +3 more sources
Resistance of Aspergillus fumigatus to Itraconazole
Scandinavian Journal of Infectious Diseases, 1998ment with the drug. The author concluded that the A. fumigatus strains acquired resistance to itraconazole during or following treatment. The author, however, failed to determine whether or not the isolates cultured from the sputa were genotypically identical. Although invasive infections by Aspergillus species are generally caused by a single genotype
Verweij, P.E., Voss, A., Meis, J.F.G.M.
openaire +4 more sources
Itraconazole in Pityriasis Versicolor
Clinical Infectious Diseases, 1987Forty-two patients with pityriasis versicolor were treated with itraconazole. Patients were allocated randomly to one of two groups; the first group (22 patients) received 200 mg of itraconazole per day for five days, and the second group (20 patients) received 100 mg per day for the same period. The study lasted 30 days.
openaire +2 more sources
Mycoses, 1995
Summary. The efficacy of two different daily doses of itraconazole (ITRA) and the combination of flucytosine (5‐FC) with ITRA in the treatment of an experimental model of cryptococcosis in hamsters was studied. Five groups of 20 animals each were inoculated by the intracardiac route with 105 cells of Cryptococcus neoformans.
J. L. Finquelievich +4 more
openaire +3 more sources
Summary. The efficacy of two different daily doses of itraconazole (ITRA) and the combination of flucytosine (5‐FC) with ITRA in the treatment of an experimental model of cryptococcosis in hamsters was studied. Five groups of 20 animals each were inoculated by the intracardiac route with 105 cells of Cryptococcus neoformans.
J. L. Finquelievich +4 more
openaire +3 more sources
Itraconazole in Human Histoplasmosis: Itraconazol bei Histoplasmose des Menschen
Mycoses, 1989Summary:A non‐comparative open trial with itraconazole in progressive forms of human histoplasmosis was carried out. Thirty two patients who completed 6 months of treatment were included; 29 suffered the chronic disseminated form; 2 exhibited a chronic pulmonary histoplasmosis and one patient presented a subacute disseminated form. Thirty patients were
A. M. Robles +3 more
openaire +2 more sources
Effect of omeprazole on the pharmacokinetics of itraconazole
European Journal of Clinical Pharmacology, 1998To investigate the effect of omeprazole on the pharmacokinetics of itraconazole.Eleven healthy volunteers received a single dose of oral itraconazole (200 mg) on days 1 and 15 and oral omeprazole (40 mg) once daily from day 2 to day 15. Itraconazole pharmacokinetics were studied on days 1 and 15.Concentrations of itraconazole were higher when it was ...
Somchai Sriwiriyajan +1 more
openaire +2 more sources
Pulmonary Sporotrichosis Treated With Itraconazole
Chest, 1993A 62-year-old woman had chronic cavitary pulmonary sporotrichosis refractory to medical management over an 8-year period. She was treated with oral itraconazole and had an apparent microbiologic and clinical response; however, the patient succumbed to progressive pulmonary hypertension.
James L. Breeling, Louis Weinstein
openaire +3 more sources
The many lives of itraconazole
Expert Opinion on Therapeutic Patents, 2003Since the discovery of the highly potent antifungal itraconazole (Sporanox®, Janssen Pharmaceutica) in the late 1970s, numerous patent applications and issued patents have appeared that describe and claim improvements for methods, manufacturing processes, formulations, enantiomers and uses for this commercially successful antifungal agent.
openaire +2 more sources
Itraconazole-Digoxin Interaction
Annals of Internal Medicine, 1992Excerpt To the Editors: Itraconazole, a triazole derivative of ketoconazole, has shown substantial promise as therapy for fungal infections (1).
openaire +2 more sources
Desensitization to itraconazole
Journal of Allergy and Clinical Immunology, 1997Robyn E O'Hehir +3 more
openaire +2 more sources